Triumph for Roche’s flu drug in phase III study

Roche has announced that the phase III CAPSTONE-2 study assessing the safety and efficacy of baloxavir marboxil in people at high risk of complications...

Follow us

NHS trusts face worryingly high levels of senior vacancies

Why is high turnover among board-level roles make a negative impact on the performance of NHS trusts?

New standards launched to improve public involvement in research

New national standards to improve the quality of public involvement in research.

The five key areas to drive growth of UK’s pharmaceutical sector

These 5 things are what pharmaceutical companies should be focusing on to maximise their growth in the UK.

The NHS is 70 – Claudia Rubin asks: what’s next?

From birthday teas to big policy, blood donor drives to special 10p coins, the 70th anniversary of the creation of the NHS is getting...

It’s time for a greater role for pharmacists in asthma management

I’ve returned from a Saturday morning in community pharmacy practice and am reflecting on the number of patients I saw with asthma. I checked...

Beyond politics; patient groups and the art of influence

“What is a patient group?”, a friend of mine enquired during one of our recent regular political discussions. It struck me afterwards that given...

NHS Digital welcomes three new, non-executive directors

John Noble, Deborah Oakley and Balram Veliath join the Board at NHS Digital, bringing their expertise to the leadership of the organisation. NHS Digital welcomes...

Jobs of the week

Two way street: Industry/patient dialogue and its role in market access

How can we make the pharma world more patient centric?

Market access focus: What is the purpose of market access?

Could market access be comparable to the Force in Star Wars, or any Disney, sci-fi, or Harry Potter film?

Market access focus: GM devolution: what has it achieved so far?

Have Greater Manchester achieved anything in three years?

Pf Magazine July 2018

Market Access Special Edition